Friday - March 27, 2026

ALK Inhibitors Clinical Trial Pipeline Expands as 15+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “ALK Inhibitors Pipeline Insight 2026” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the ALK Inhibitors pipeline landscape. It covers the ALK Inhibitors Pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading

PARP Inhibitors Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “PARP inhibitor Pipeline Insights 2026” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the PARP inhibitor pipeline landscape. It covers the PARP inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading

NLRP3 Protein Inhibitors Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “NLRP3 Protein Inhibitors Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the NLRP3 Protein Inhibitors pipeline landscape. It covers the NLRP3 Protein Inhibitors Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading

Lupus Nephritis Market to Surpass USD 1.8 Billion by 2034 | 20+ Companies and Emerging Therapies Driving Growth, analyses DelveInsight

Lupus Nephritis Market Prominent Lupus Nephritis companies working in the market are Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka Pharmaceutical, MorphoSys, Vertice Pharma, Pharmaceutical Associates Inc., Sun Pharmaceutical, Abbott, Johnson & Johnson Private Limited, Bayer, Sanofi, Sumitomo Corporation, … Continue reading

Metastatic Triple-Negative Breast Cancer Market: Strong Growth Potential Across APAC Through 2036, Driven by Innovation and Rising Disease Burden | DelveInsight

Metastatic Triple-Negative Breast Cancer Market Leading Metastatic Triple-Negative Breast Cancer companies include AstraZeneca, Takeda, Novartis, Roche, Eli Lilly, Merck, Bristol-Myers Squibb, Gilead Sciences, and others. DelveInsight’s report, “Metastatic Triple Negative Breast Cancer Patient Pool Analysis, Market Size, and Market Forecast … Continue reading